763 Shares in Danaher Co. (NYSE:DHR) Purchased by L. Roy Papp & Associates LLP

L. Roy Papp & Associates LLP bought a new stake in Danaher Co. (NYSE:DHR) during the third quarter, Holdings Channel reports. The institutional investor bought 763 shares of the conglomerate’s stock, valued at approximately $212,000.

A number of other hedge funds have also made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter valued at $25,000. nVerses Capital LLC acquired a new position in Danaher in the 2nd quarter worth about $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the 1st quarter worth about $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at about $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher in the 2nd quarter valued at approximately $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday. Leerink Partners raised their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday. Barclays cut their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, TD Cowen upped their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Performance

Danaher stock traded down $2.61 during mid-day trading on Friday, reaching $245.39. The company had a trading volume of 3,226,925 shares, compared to its average volume of 2,743,044. The company has a 50 day moving average of $269.52 and a 200-day moving average of $260.42. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $181.76 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. On average, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.